VGA039 (latarcibart) - (VIVID-6)

July 13, 2026: Incyte (NASDAQ: INCY) reported complete safety and efficacy results from all patients (n=16) in a Phase 1/2 multidose study of VGA039 (latarcibart), a Protein S–targeting investigational monoclonal antibody for prophylaxis in von Willebrand disease (VWD). Data were presented in an oral session at the ISTH 2026 Congress in Paris.

Across all VWD types and bleed categories, latarcibart achieved an 81% median reduction in annualized bleeding rate (ABR). Patients switching from prior VWF-containing IV prophylaxis (multiple weekly infusions) had 75–100% bleed reductions. Among patients not previously on IV prophylaxis who had historical ABR >12 (7 patients), ABR reductions ranged 46–100%, with 6/7 achieving >73% reductions. Breakthrough bleeds treated with VWF were reduced by ~86%, and 70% of patients with prior VWF-treated bleeds had none on treatment. All participants completed six doses with subcutaneous maintenance dosing every four weeks and rolled into an ongoing open-label extension.

Safety was described as well tolerated; related TEAEs were two Grade 2 headaches (one patient) and one Grade 1 injection-site reaction. One unrelated serious AE of severe GI bleeding occurred in a patient with prior severe GI bleeding.

The pivotal Phase 3 VIVID-6 trial (NCT07115004) is currently enrolling. The release also notes Incyte acquired latarcibart via its July 2026 acquisition of Vega Therapeutics.